We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Mayo Clinic investigators have discovered a gene mutation causing chaotic electrical activation of the heart muscle and atrial fibrillation (AF), a common heart-rhythm disturbance affecting millions of Americans.
In a major Canadian biotech deal, drug developer Resverlogix, located in Calgary, Alberta, has licensed its cardiovascular stent medication to Minneapolis-based Medtronic for $340 million.
The FDA issued a June 1 warning letter to Dux Industries of Oxnard, Calif., citing the company for failing to document quality controls and management review procedures, and for lacking a system to receive and review product complaints.
S3 Investment Company, Inc., announced that subsidiary SINO UJE, Ltd. has been awarded distribution rights in China to the HandiLab line of medical diagnostic tests from Zonda Incorporated, a California-based company.
Abbott Laboratories Inc. is finalizing a patent infringement case settlement with Israeli company Medinol Ltd. that could free Abbott's Xience drug-coated stent medical device from an entanglement as Abbott works to bring the product to the U.S. market.